Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
OPERATING ACTIVITIES
Net income	$ 170,746	$ 108,185
Adjustments to reconcile net income to net cash provided by operating activities:
Share-based compensation expense	17,469	12,679
Deferred income taxes	4,699	962
Amortization of investments	521	245
Depreciation and amortization	9,757	4,645
Impairment of goodwill and intangibles	0	719
Loss on disposal of property and equipment	0	95
Imputed interest for contingent consideration and in-process R&D	2,382	588
Other compensation expense	1,059	494
Changes in operating assets and liabilities, net of business acquisition:
Accounts receivable	(17,887)	(2,883)
Inventories	20	4,270
Prepaid income taxes	(9,970)	0
Prepaid expenses and other current assets	225	1,175
Accounts payable	20,306	(2,569)
Accrued compensation	6,530	(10,780)
Sales-related reserves	(8,457)	(1,786)
Accrued royalties	11,235	7,060
Income taxes payable	(1,535)	(2,684)
Other accrued liabilities	(1,714)	2,555
Other non-current liabilities	45	21
Net cash flows provided by operating activities	205,431	122,991
INVESTING ACTIVITIES
Purchase of property and equipment	(8,266)	(1,138)
Purchase of short-term investments	(33,570)	(52,001)
Proceeds from maturities of short-term investments	41,178	116,206
Acquisition of BioVectra, net of cash acquired	0	(46,692)
Contingent consideration payment related to BioVectra acquisition	(4,581)	0
Restricted cash associated with the acquisition of Synacthen	0	(75,000)
Acquisition of Synacthen	0	(60,000)
Annual cash payment for Synacthen	(25,000)	0
Proceeds from sale of Doral	0	700
Deposits and other assets	766	0
Net cash flows used in investing activities	(29,473)	(117,925)
FINANCING ACTIVITIES
Repayment of funded long-term debt	(591)	(613)
Repayment of other long-term debt	(232)	(212)
Income tax benefit realized from share-based compensation plans	17,699	5,173
Issuance of common stock, net	1,519	6,943
Repurchase of common stock	(2,146)	0
Dividends paid	(36,457)	(14,887)
Net cash flows used in financing activities	(20,208)	(3,596)
Effect of cash on changes in exchange rates	89	(313)
Increase in cash and cash equivalents	155,839	1,157
Cash and cash equivalents at beginning of period	175,840	80,608
Cash and cash equivalents at end of period	331,679	81,765
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	294	380
Cash paid for income taxes	78,884	49,234
Dividend payable	18,426	15,000
Incremental fair value of assets acquired, net		80,698
Less: fair value of contingent consideration		(30,383)
Fair value of assets acquired		50,315
Loss on foreign exchange rate	94	488
Total cash paid for acquisition of BioVectra		$ 50,803